Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche's Ocrevus, although ...

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› by Doug Mahoney The U.S. Wire & Cable 50 FT. Extreme All-Weather Extension Cord ...

For more than 40 years, investors have trusted Morningstar to tell it like it is. Our independent analysis and investment research tools uncover how well an investment serves investors—and no one else ...

U.S. 3 Year Treasury Note 0.0080 3.6740% U.S. 5 Year Treasury Note 0.0320 3.7770% U.S. 7 Year Treasury Note 0.0380 3.9660% ...